Breakpoint Therapeutics GmbH
October 18, 2023
Franciscan C
Oncology
Breakpoint Therapeutics GmbH is a pre-clinical stage company dedicated to the discovery and development of novel oncology drugs that target the DNA damage response (DDR) in cancer cells.
Company Type
Privately Funded
Website
http://www.breakpointtx.com
CEO/Top Company Official
Daniel Speidel & Jon Hollick
Lead Product in Development
Pol Theta (PolQ) inhibitor
Number Of Unlicensed Products
2
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)